The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine-The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation

Toxins

Volumn 5, Issue 2, 2013, Pages 336-362

  Reikvam, Håkon ^a,b   Fredly, Hanne ^a,b   Kittang, Astrid Olsnes ^b   Bruserud, Øystein ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myeloid leukemia; Chemokines; Systemic profiles

Indexed keywords

AZACITIDINE; CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RETINOIC ACID; TUMOR NECROSIS FACTOR RECEPTOR 1; VALPROIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; BLOOD LEVEL; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; HUMAN; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; STANDARDIZATION;

CYTOKINES; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875239728     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins5020336     Document Type: Review

References (128)

1. Kittang, A.O.; Hatfield, K.; Sand, K.; Reikvam, H.; Bruserud, O. The chemokine network in acute myelogenous leukemia: Molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr. Top. Microbiol. Immunol. 2010, 341, 149-172.
2. Vereecque, R.; Saudemont, A.; Quesnel, B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004, 18, 1223-1230.
3. Garcia, G.; Godot, V.; Humbert, M. New chemokine targets for asthma therapy. Curr. Allergy Asthma Rep. 2005, 5, 155-160.
4. Lake, R.A.; Robinson, B.W. Immunotherapy and chemotherapy-A practical partnership. Nat. Rev. Cancer 2005, 5, 397-405.
5. Yang, D.; Chen, Q.; Hoover, D.M.; Staley, P.; Tucker, K.D.; Lubkowski, J.; Oppenheim, J.J. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J. Leukoc. Biol. 2003, 74, 448-455.
6. Charo, I.F.; Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354, 610-621.
7. Bruserud, O.; Wendelboe, O. Biological treatment in acute myelogenous leukaemia: How should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin. Biol. Ther. 2001, 1, 1005-1016.
8. Cao, W.; Tang, S.; Yuan, H.; Wang, H.; Zhao, X.; Lu, H. Mycobacterium tuberculosis antigen Wag31 induces expression of C-chemokine XCL2 in macrophages. Curr. Microbiol. 2008, 57, 189-194.
9. Kennedy, J.; Kelner, G.S.; Kleyensteuber, S.; Schall, T.J.; Weiss, M.C.; Yssel, H.; Schneider, P.V.; Cocks, B.G.; Bacon, K.B.; Zlotnik, A. Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 1995, 155, 203-209.
10. Hieshima, K.; Ohtani, H.; Shibano, M.; Izawa, D.; Nakayama, T.; Kawasaki, Y.; Shiba, F.; Shiota, M.; Katou, F.; Saito, T.; Yoshie, O. CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity. J. Immunol. 2003, 170, 1452-1461.
11. Wang, W.; Soto, H.; Oldham, E.R.; Buchanan, M.E.; Homey, B.; Catron, D.; Jenkins, N.; Copeland, N.G.; Gilbert, D.J.; Nguyen, N.; et al. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J. Biol. Chem. 2000, 275, 22313-22323.
12. Nowak, A.K.; Robinson, B.W.; Lake, R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003, 63, 4490-4496.
13. Bergmann-Leitner, E.S.; Abrams, S.I. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol. Immunother. 2001, 50, 445-455.
14. Nomiyama, H.; Hieshima, K.; Nakayama, T.; Sakaguchi, T.; Fujisawa, R.; Tanase, S.; Nishiura, H.; Matsuno, K.; Takamori, H.; Tabira, Y.; et al. Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. Int. Immunol. 2001, 13, 1021-1029.
15. Joubert, P.; Lajoie-Kadoch, S.; Wellemans, V.; Letuve, S.; Tulic, M.K.; Halayko, A.J.; Hamid, Q. Expression and regulation of CCL15 by human airway smooth muscle cells. Clin. Exp. Allergy 2012, 42, 85-94.
16. Sarafi, M.N.; Garcia-Zepeda, E.A.; MacLean, J.A.; Charo, I.F.; Luster, A.D. Murine monocyte chemoattractant protein (MCP)-5: A novel CC chemokine that is a structural and functional homologue of human MCP-1. J. Exp. Med. 1997, 185, 99-109.
17. Moore, B.B.; Murray, L.; Das, A.; Wilke, C.A.; Herrygers, A.B.; Toews, G.B. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2006, 35, 175-181.
18. Lean, J.M.; Murphy, C.; Fuller, K.; Chambers, T.J. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J. Cell. Biochem. 2002, 87, 386-393.
19. Moser, B.; Wolf, M.; Walz, A.; Loetscher, P. Chemokines: Multiple levels of leukocyte migration control. Trends Immunol. 2004, 25, 75-84.
20. Bruserud, O.; Ryningen, A.; Olsnes, A.M.; Stordrange, L.; Oyan, A.M.; Kalland, K.H.; Gjertsen, B.T. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007, 92, 332-341.
21. Mantovani, A.; Sica, A.; Sozzani, S.; Allavena, P.; Vecchi, A.; Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25, 677-686.
22. McColl, S.R. Chemokines and dendritic cells: A crucial alliance. Immunol. Cell Biol. 2002, 80, 489-496.
23. Lebre, M.C.; Burwell, T.; Vieira, P.L.; Lora, J.; Coyle, A.J.; Kapsenberg, M.L.; Clausen, B.E.; De Jong, E.C. Differential expression of inflammatory chemokines by Th1-and Th2-cell promoting dendritic cells: A role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol. Cell Biol. 2005, 83, 525-535.
24. Rossi, D.; Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000, 18, 217-242.
25. Ma, B.; Zhu, Z.; Homer, R.J.; Gerard, C.; Strieter, R.; Elias, J.A. The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J. Immunol. 2004, 172, 1872-1881.
26. Jun, K.J.; Lee, M.J.; Shin, D.C.; Woo, M.Y.; Kim, K.; Park, S. Identification of CCL1 as a gene differentially expressed in CD4 T cells expressing TIM-3. Immune Netw. 2011, 11, 203-209.
27. Schmitz, J.M.; McCracken, V.J.; Dimmitt, R.A.; Lorenz, R.G. Expression of CXCL15 (Lungkine) in murine gastrointestinal, urogenital, and endocrine organs. J. Histochem. Cytochem. 2007, 55, 515-524.
28. Augsten, M.; Hagglof, C.; Olsson, E.; Stolz, C.; Tsagozis, P.; Levchenko, T.; Frederick, M.J.; Borg, A.; Micke, P.; Egevad, L.; Ostman, A. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc. Natl. Acad. Sci. USA 2009, 106, 3414-3419.
29. Meuter, S.; Moser, B. Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cytokine 2008, 44, 248-255.
30. Pillai, M.M.; Iwata, M.; Awaya, N.; Graf, L.; Torok-Storb, B. Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood 2006, 107, 3520-3526.
31. Linge, H.M.; Collin, M.; Nordenfelt, P.; Morgelin, M.; Malmsten, M.; Egesten, A. The human CXC chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membranedisrupting properties and is antibacterial. Antimicrob. Agents Chemother. 2008, 52, 2599-2607.
32. Kasper, B.; Petersen, F. Molecular pathways of platelet factor 4/CXCL4 signaling. Eur. J. Cell Biol. 2011, 90, 521-526.
33. Allen, S.J.; Crown, S.E.; Handel, T.M. Chemokine: Receptor structure, interactions, and antagonism. Ann. Rev. Immunol. 2007, 25, 787-820.
34. Bruserud, O.; Kittang, A.O. The chemokine system in experimental and clinical hematology. Curr. Top Microbiol. Immunol. 2010, 341, 3-12.
35. Hatfield, K.J.; Olsnes, A.M.; Gjertsen, B.T.; Bruserud, O. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr. Cancer Drug Targ. 2005, 5, 229-248.
36. Hatfield, K.; Oyan, A.M.; Ersvaer, E.; Kalland, K.H.; Lassalle, P.; Gjertsen, B.T.; Bruserud, O. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br. J. Haematol. 2009, 144, 53-68.
37. Hatfield, K.; Ryningen, A.; Corbascio, M.; Bruserud, O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer 2006, 119, 2313-2321.
38. Hatfield, K.J.; Reikvam, H.; Bruserud, O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr. Med. Chem. 2010, 17, 4448-4461.
39. Fredly, H.; Reikvam, H.; Gjertsen, B.T.; Bruserud, O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am. J. Hematol. 2012, 87, 368-376.
40. Kornblau, S.M.; McCue, D.; Singh, N.; Chen, W.; Estrov, Z.; Coombes, K.R. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010, 116, 4251-4261.
41. Van Etten, R.A. Aberrant cytokine signaling in leukemia. Oncogene 2007, 26, 6738-6749.
42. Reikvam, H.; Hatfield, K.; Fredly, H.; Nepstad, I.; Mosevoll, K.A.; Bruserud, Ø. The angiorgeulatory cytokine network in human acute myeloid leukemia-From leukemogenesis via remission to stem cell transplantasion. Eur. Cytokine Netw. 2012, 23, 140-153.
43. Mazur, G.; Wrobel, T.; Butrym, A.; Kapelko-Slowik, K.; Poreba, R.; Kuliczkowski, K. Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. Neoplasma 2007, 54, 285-289.
44. Olsnes, A.M.; Motorin, D.; Ryningen, A.; Zaritskey, A.Y.; Bruserud, O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): Local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol. Immunother. 2006, 55, 830-840.
45. Struyf, S.; Schutyser, E.; Gouwy, M.; Gijsbers, K.; Proost, P.; Benoit, Y.; Opdenakker, G.; Van Damme, J.; Laureys, G. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am. J. Pathol. 2003, 163, 2065-2075.
46. Negaard, H.F.; Iversen, N.; Bowitz-Lothe, I.M.; Sandset, P.M.; Steinsvik, B.; Ostenstad, B.; Iversen, P.O. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009, 23, 162-169.
47. Hsu, H.C.; Lee, Y.M.; Tsai, W.H.; Jiang, M.L.; Ho, C.H.; Ho, C.K.; Wang, S.Y. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002, 63, 64-69.
48. Ostermann, H.; Rothenburger, M.; Mesters, R.M.; van de Loo, J.; Kienast, J. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br. J. Haematol. 1994, 88, 332-337.
49. Bruserud, O.; Halstensen, A.; Peen, E.; Solberg, C.O. Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. Leuk. Lymphoma 1996, 23, 423-430.
50. Schonbohn, H.; Schuler, M.; Kolbe, K.; Peschel, C.; Huber, C.; Bemb, W.; Aulitzky, W.E. Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann. Hematol. 1995, 71, 161-168.
51. Olsnes, A.M.; Hatfield, K.J.; Bruserud, O. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J. BUON 2009, 14, S131-S140.
52. Kalinkovich, A.; Tavor, S.; Avigdor, A.; Kahn, J.; Brill, A.; Petit, I.; Goichberg, P.; Tesio, M.; Netzer, N.; Naparstek, E.; et al. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 2006, 66, 11013-11020.
53. Feng, X.; Scheinberg, P.; Wu, C.O.; Samsel, L.; Nunez, O.; Prince, C.; Ganetzky, R.D.; McCoy, J.P., Jr.; Maciejewski, J.P.; Young, N.S. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011, 96, 602-606.
54. Baker, S.J.; Rane, S.G.; Reddy, E.P. Hematopoietic cytokine receptor signaling. Oncogene 2007, 26, 6724-6737.
55. Russell, N.H. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev. 1992, 6, 149-156.
56. Elbaz, O.; Shaltout, A. Implication of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL-3) in children with acute myeloid leukaemia (AML); malignancy. Hematology 2001, 5, 383-388.
57. Tao, M.; Li, B.; Nayini, J.; Andrews, C.B.; Huang, R.W.; Devemy, E.; Song, S.; Venugopal, P.; Preisler, H.D. SCF, IL-1β, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine 2000, 12, 699-707.
58. Tsimberidou, A.M.; Estey, E.; Wen, S.; Pierce, S.; Kantarjian, H.; Albitar, M.; Kurzrock, R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008, 113, 1605-1613.
59. Foss, B.; Nesthus, I.; Bergheim, J.; Bruserud, O. Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating infections. Platelets 1999, 10, 17-23.
60. Panteli, K.E.; Hatzimichael, E.C.; Bouranta, P.K.; Katsaraki, A.; Seferiadis, K.; Stebbing, J.; Bourantas, K.L. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br. J. Haematol. 2005, 130, 709-715.
61. Kim, J.G.; Sohn, S.K.; Kim, D.H.; Baek, J.H.; Lee, N.Y.; Suh, J.S.; Chae, S.C.; Lee, K.S.; Lee, K.B. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk. Lymphoma 2005, 46, 885-891.
62. Aguayo, A.; Kantarjian, H.M.; Estey, E.H.; Giles, F.J.; Verstovsek, S.; Manshouri, T.; Gidel, C.; O'Brien, S.; Keating, M.J.; Albitar, M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002, 95, 1923-1930.
63. Bruserud, O.; Foss, B.; Petersen, H. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: Studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Eur. Cytokine Netw. 2001, 12, 231-238.
64. Chou, W.-C.; Huang, H.-H.; Hou, H.-A.; Chen, C.-Y.; Tang, J.-L.; Yao, M.; Tsay, W.; Ko, B.-S.; Wu, S.-J.; Huang, S.-Y.; et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010, 116, 4086-4094.
65. Hatfield, K.J.; Lassalle, P.; Leiva, R.A.; Lindas, R.; Wendelboe, O.; Bruserud, O. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology 2011, 16, 351-356.
66. Reikvam, H.; Hatfield, K.J.; Oyan, A.M.; Kalland, K.H.; Kittang, A.O.; Bruserud, O. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: Release profile and pharmacological modulation. Eur. J. Haematol. 2010, 84, 239-251.
67. Bruserud, O.; Gjertsen, B.T.; Foss, B.; Huang, T.S. New strategies in the treatment of acute myelogenous leukemia (AML): In vitro culture of aml cells-The present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001, 19, 1-11.
68. Clarke, C.; Smyth, M.J. Calreticulin exposure increases cancer immunogenicity. Nat. Biotechnol. 2007, 25, 192-193.
69. Fitzgerald, K.A. The Cytokine: FactsBook; Academic Press: Amsterdam, The Netherlands, 2001.
70. Fredly, H.; Ersvaer, E.; Gjertsen, B.T.; Bruserud, O. Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol. Rep. 2011, 25, 1549-1556.
71. Foss, B.; Hervig, T.; Bruserud, O. Connexins are active participants of hematopoietic stem cell regulation. Stem Cells Dev. 2009, 18, 807-812.
72. Bruserud, O.; Gjertsen, B.T.; von Volkman, H.L. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: Studies of native AML blasts and AML cell lines. J. Hematother. Stem Cell Res. 2000, 9, 923-932.
73. Bruserud, O. Bidirectional crosstalk between platelets and monocytes initiated by toll-like receptor: An important step in the early defense against fungal infections? Platelets 2013, 24, 85-97.
74. Bergkvist, A.; Rusnakova, V.; Sindelka, R.; Garda, J.M.; Sjogreen, B.; Lindh, D.; Forootan, A.; Kubista, M. Gene expression profiling-Clusters of possibilities. Methods 2010, 50, 323-335.
75. Reikvam, H.; Mosevoll, K.A.; Melve, G.K.; Gunther, C.C.; Sjo, M.; Bentsen, P.T.; Bruserud, O. The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biol. Blood Marrow Transplant. 2012, 18, 190-199.
76. Valk, P.J.; Verhaak, R.G.; Beijen, M.A.; Erpelinck, C.A.; Barjesteh van Waalwijk van Doorn-Khosrovani, S.; Boer, J.M.; Beverloo, H.B.; Moorhouse, M.J.; van der Spek, P.J.; Lowenberg, B.; Delwel, R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350, 1617-1628.
77. Bullinger, L.; Dohner, K.; Bair, E.; Frohling, S.; Schlenk, R.F.; Tibshirani, R.; Dohner, H.; Pollack, J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 2004, 350, 1605-1616.
78. Verhaak, R.G.; Wouters, B.J.; Erpelinck, C.A.; Abbas, S.; Beverloo, H.B.; Lugthart, S.; Lowenberg, B.; Delwel, R.; Valk, P.J. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009, 94, 131-134.
79. Kornblau, S.M.; Tibes, R.; Qiu, Y.H.; Chen, W.; Kantarjian, H.M.; Andreeff, M.; Coombes, K.R.; Mills, G.B. Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113, 154-164.
80. Reikvam, H.; Hatfield, K.J.; Ersvaer, E.; Hovland, R.; Skavland, J.; Gjertsen, B.T.; Petersen, K.; Bruserud, O. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status-Consequences and potentials for pharmacological intervention. Br. J. Haematol. 2012, 156, 468-480.
81. Jorgensen, K.M.; Hjelle, S.M.; Oye, O.K.; Puntervoll, P.; Reikvam, H.; Skavland, J.; Anderssen, E.; Bruserud, O.; Gjertsen, B.T. Untangling the intracellular signalling network in cancer-A strategy for data integration in acute myeloid leukaemia. J. Proteomics 2011, 74, 269-281.
82. Paczesny, S.; Krijanovski, O.I.; Braun, T.M.; Choi, S.W.; Clouthier, S.G.; Kuick, R.; Misek, D.E.; Cooke, K.R.; Kitko, C.L.; Weyand, A.; et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113, 273-278.
83. Wernicke, C.; Grunewald, T.; Juenger, H.; Kuci, S.; Kuci, Z.; Koehl, U.; Mueller, I.; Doering, M.; Peters, C.; Lawitschka, A.; et al. Mesenchymal stromal cells for treatment of steroid-refractory GvHD: A review of the literature and two pediatric cases. Int. Arch. Med. 2011, 4, 27.
84. Prockop, D.J.; Oh, J.Y. Medical therapies with adult stem/progenitor cells (MSCs): A backward journey from dramatic results in vivo to the cellular and molecular explanations. J. Cell Biochem. 2012, 113, 1460-1469.
85. Kraman, M.; Bambrough, P.J.; Arnold, J.N.; Roberts, E.W.; Magiera, L.; Jones, J.O.; Gopinathan, A.; Tuveson, D.A.; Fearon, D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 2010, 330, 827-830.
86. Le Blanc, K.; Rasmusson, I.; Sundberg, B.; Gotherstrom, C.; Hassan, M.; Uzunel, M.; Ringden, O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363, 1439-1441.
87. Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M.E.; Remberger, M.; et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008, 371, 1579-1586.
88. Aggarwal, S.; Pittenger, M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105, 1815-1822.
89. Glennie, S.; Soeiro, I.; Dyson, P.J.; Lam, E.W.; Dazzi, F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105, 2821-2827.
90. Egea, V.; von Baumgarten, L.; Schichor, C.; Berninger, B.; Popp, T.; Neth, P.; Goldbrunner, R.; Kienast, Y.; Winkler, F.; Jochum, M.; Ries, C. TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma. Cell Death Differ. 2011, 18, 853-863.
91. Cao, W.; Yang, Y.; Wang, Z.; Liu, A.; Fang, L.; Wu, F.; Hong, J.; Shi, Y.; Leung, S.; Dong, C.; Zhang, J.Z. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity 2011, 35, 273-284.
92. Pogacic, V.; Bullock, A.N.; Fedorov, O.; Filippakopoulos, P.; Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007, 67, 6916-6924.
93. Tsykunova, G.; Reikvam, H.; Hovland, R.; Bruserud, O. The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status. Leukemia 2012, 26, 557-559.
94. Studeny, M.; Marini, F.C.; Dembinski, J.L.; Zompetta, C.; Cabreira-Hansen, M.; Bekele, B.N.; Champlin, R.E.; Andreeff, M. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 2004, 96, 1593-1603.
95. Hall, B.; Dembinski, J.; Sasser, A.K.; Studeny, M.; Andreeff, M.; Marini, F. Mesenchymal stem cells in cancer: Tumor-associated fibroblasts and cell-based delivery vehicles. Int. J. Hematol. 2007, 86, 8-16.
96. Shi, Y.; Su, J.; Roberts, A.I.; Shou, P.; Rabson, A.B.; Ren, G. How mesenchymal stem cells interact with tissue immune responses. Trend Immunol. 2012, 33, 136-143.
97. Roodhart, J.M.; Daenen, L.G.; Stigter, E.C.; Prins, H.J.; Gerrits, J.; Houthuijzen, J.M.; Gerritsen, M.G.; Schipper, H.S.; Backer, M.J.; van Amersfoort, M.; et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011, 20, 370-383.
98. Apelseth, T.O.; Hervig, T.; Wentzel-Larsen, T.; Petersen, K.; Reikvam, H.; Bruserud, O. A prospective observational study of the effect of platelet transfusions on levels of plateletderived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. Eur. Cytokine Netw. 2011, 22, 52-62.
99. Mosevoll, K.A.; Akkok, C.A.; Hervig, T.; Melve, G.; Bruserud, Ø.; Reikvam, H. Apheresis-induced alterations in systemic cytokine levels-Studies in myeloma patients undergoing stem cell harvesting and healthy individuals undergoing platelet harvesting. Cythotherapy 2013, in press.
100. Pollyea, D.A.; Kohrt, H.E.; Gallegos, L.; Figueroa, M.E.; Abdel-Wahab, O.; Zhang, B.; Bhattacharya, S.; Zehnder, J.; Liedtke, M.; Gotlib, J.R.; et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012, 26, 893-901.
101. Aivado, M.; Spentzos, D.; Germing, U.; Alterovitz, G.; Meng, X.Y.; Grall, F.; Giagounidis, A.A.; Klement, G.; Steidl, U.; Otu, H.H.; et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc. Natl. Acad. Sci. USA 2007, 104, 1307-1312.
102. Kordasti, S.Y.; Afzali, B.; Lim, Z.; Ingram, W.; Hayden, J.; Barber, L.; Matthews, K.; Chelliah, R.; Guinn, B.; Lombardi, G.; et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br. J. Haematol. 2009, 145, 64-72.
103. WHO. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed.; International Agency for Cancer: Lyon, France, 2008.
104. Ferrara, J.L.; Levine, J.E.; Reddy, P.; Holler, E. Graft-versus-host disease. Lancet 2009, 373, 1550-1561.
105. Wolf, D.; von Lilienfeld-Toal, M.; Wolf, A.M.; Schleuning, M.; von Bergwelt-Baildon, M.; Held, S.A.; Brossart, P. Novel treatment concepts for graft-versus-host disease. Blood 2012, 119, 16-25.
106. Ito, W.; Takeda, M.; Ueki, S.; Tanigai, T.; Kayaba, H.; Chihara, J. Effect of the hepatocyte growth factor on allergic inflammatory cells. Int. Arch. Allergy Immunol. 2010, 152, 96-100.
107. Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; de Ritis, D.G.; Curti, A.; Danese, S.; Pessina, G.; Pandolfi, S.; Natoni, F.; et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006, 108, 218-227.
108. Ito, W.; Takeda, M.; Tanabe, M.; Kihara, J.; Kato, H.; Chiba, T.; Yamaguchi, K.; Ueki, S.; Kanehiro, A.; Kayaba, H.; Chihara, J. Anti-allergic inflammatory effects of hepatocyte growth factor. Int. Arch. Allergy Immunol. 2008, 146, 82-87.
109. Dietrich, S.; Falk, C.S.; Benner, A.; Karamustafa, S.; Hahn, E.; Andrulis, M.; Hegenbart, U.; Ho, A.D.; Dreger, P.; Luft, T. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol. Blood Marrow Transplant. 2013, 19, 22-27.
110. Toubai, T.; Tanaka, J.; Paczesny, S.; Shono, Y.; Reddy, P.; Imamura, M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): Are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr. Stem Cell Res. Ther. 2012, 7, 229-239.
111. Paczesny, S.; Braun, T.M.; Levine, J.E.; Hogan, J.; Crawford, J.; Coffing, B.; Olsen, S.; Choi, S.W.; Wang, H.; Faca, V.; et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci. Transl. Med. 2010, 2, 13ra2.
112. Harris, A.C.; Ferrara, J.L.; Braun, T.M.; Holler, E.; Teshima, T.; Levine, J.E.; Choi, S.W.; Landfried, K.; Akashi, K.; Vander Lugt, M.; et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012, 119, 2960-2963.
113. Ferrara, J.L.; Harris, A.C.; Greenson, J.K.; Braun, T.M.; Holler, E.; Teshima, T.; Levine, J.E.; Choi, S.W.; Huber, E.; Landfried, K.; et al. Regenerating islet-derived 3-α is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118, 6702-6708.
114. Levine, J.E.; Logan, B.R.; Wu, J.; Alousi, A.M.; Bolanos-Meade, J.; Ferrara, J.L.; Ho, V.T.; Weisdorf, D.J.; Paczesny, S. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A blood and marrow transplant clinical trials Nnetwork study. Blood 2012, 119, 3854-3860.
115. Paczesny, S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013, 121, 585-594.
116. Allegretti, M.; Cesta, M.C.; Garin, A.; Proudfoot, A.E. Current status of chemokine receptor inhibitors in development. Immunol. Lett. 2012, 145, 68-78.
117. Melve, G.K.; Ersvssr, E.; Kittang, A.O.; Bruserud, O. The chemokine system in allogeneic stem-cell transplantation: A possible therapeutic target? Expert Rev. Hematol. 2011, 4, 563-576.
118. Busca, A. The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert Opin. Biol. Ther. 2011, 11, 687-697.
119. Emery, P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 2012, 51, v22-v30.
120. Choi, S.W.; Stiff, P.; Cooke, K.; Ferrara, J.L.; Braun, T.; Kitko, C.; Reddy, P.; Yanik, G.; Mineishi, S.; Paczesny, S.; et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: Lower TNFR1 levels correlate with better outcomes. Biol. Blood Marrow Transplant. 2012, 18, 1525-1532.
121. Cecchi, F.; Rabe, D.C.; Bottaro, D.P. Targeting the HGF/Met signalling pathway in cancer. Eur. J. Cancer. 2010, 46, 1260-1270.
122. Naran, S.; Zhang, X.; Hughes, S.J. Inhibition of HGF/MET as therapy for malignancy. Expert Opin. Ther. Targ. 2009, 13, 569-581.
123. Bruserud, O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies. Leukemia 1999, 13, 1175-1187.
124. Bruserud, O.; Bergheim, J.; Shammas, F.V.; Nesthus, I. Serum concentrations of tumour necrosis factor-alpha during chemotherapy-induced leukopenia in patients with acute leukaemia and bacterial infections. Leuk. Res. 1994, 18, 415-421.
125. Bruserud, O.; Hamann, W.; Patel, S.; Ehninger, G.; Pawelec, G. IL2-and IL4-dependent proliferation of T-cell clones derived early after allogeneic bone marrow transplantation: Studies of patients with chronic myelogenous leukaemia. Eur. J. Haematol. 1992, 48, 221-227.
126. Bruserud, O.; Hamann, W.; Patel, S.; Ehninger, G.; Schmidt, H.; Pawelec, G. IFN-γ and TNF-α secretion by CD4+ and CD8+ TCR α β + T-cell clones derived early after allogeneic bone marrow transplantation. Eur. J. Haematol. 1993, 51, 73-79.
127. Mosevold, K.A.; Bruserud, O. Circadian variations do not have a major impact on serum levels of soluble (S) L-selectin (CD63L), S-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals. Scand. J. Clin. Lab. Invest. 2002, 62, 75-79.
128. Glenjen, N.; Mosevoll, K.A.; Bruserud, O. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int. J. Cancer 2002, 101, 86-94.